Integrated Risk Information System (IRIS); Request for Chemical Substance Nominations for 2011 Program, 63827-63830 [2010-26159]
Download as PDF
<![CDATA[
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
Under section 402 of the American
Recovery and Reinvestment Act
(Recovery Act), 42 U.S.C. 16421a, Public
Law 111–5, 123 Stat. 141, Div A, Title
IV, section 402 (2009) (adding Section
301 to the Hoover Power Plant Act of
1984 [Public Law 98–381, Title III,
section 301]), Western may borrow
funds from the United States Treasury
to construct, finance, facilitate, plan,
operate, maintain, and/or study
construction of new or upgraded electric
power transmission lines and related
facilities with at least one terminus in
Western’s marketing area, that deliver or
facilitate the delivery of power from
renewable resources constructed or
reasonably expected to be constructed
after the date of enactment of the
Recovery Act. In order to implement
section 402, on March 4, 2009, Western
published a Notice of Proposed Program
and Request for Public Comments in the
Federal Register (74 FR 9391)
describing its proposed Transmission
Infrastructure Program (TIP) and
soliciting public input on that program.
After considering the comments
received on its March 4 notice, Western
published its final TIP Notice of
Program on May 14, 2009 (74 FR 22732).
Western also published a Notice of
Availability of Request for Interest on
March 4, 2009, (74 FR 9391) that
solicited interest in proposed
transmission projects that resulted in
the submission of over 200 SOIs,
including a SOI for the TWE Project.
Western is evaluating its potential
participation in the TWE Project. The
TWE Project is proposed as a 725-mile,
3,000-megawatt (MW), 600-kilovolt
(kV), two-terminal, direct-current (DC)
transmission system with terminals in
Wyoming and Nevada and a potential
interconnection at the Intermountain
Power Project near Delta, Utah. The
northern substation/converter station
would be located near the Platte
substation, in Carbon County, Wyoming.
The southern substation/converter
station would be located in southern
Nevada near the Eldorado Valley. The
northern terminal of the line is
anticipated to interconnect with the
planned 500-kV alternating current (AC)
system that PacifiCorp has proposed as
part of the Energy Gateway project. The
southern terminal of the line would be
interconnected with the 500-kV AC
substations within the Eldorado Valley,
where power can be wheeled to the
various markets in the region. The
estimated cost for the project is $3
billion and the planned in-service date
is 2015. Western anticipates that it will
be able to make approximately 250 MW
of unidirectional surplus transmission
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
capacity available from the Carbon
County, Wyoming area to the Clark
County, Nevada area.
In this notice, Western solicits SOIs to
allow Western to determine the level of
interest in Western’s portion of longterm firm transmission service on the
TWE Project. Information received
through this effort may assist Western in
acquiring TWE Project support and
approval. Specifically, Western is
soliciting any and all interest from
entities looking to transfer energy from
the Carbon County, Wyoming area to the
Clark County, Nevada area. Western’s
rate would be cost-based; however,
Western does not currently have
sufficient information to estimate a rate.
An expression of interest in purchasing
this long-term firm transmission service
made by submitting a SOI is not binding
or promissory. SOIs submitted with
respect to this notice should, at a
minimum, include the following
information:
1. Name and general description of
the entity submitting the SOI.
2. Name, mailing address, telephone
number, facsimile number, and e-mail
address of that entity’s primary contact.
3. Preferred interconnection points.
4. Description of the resources the
proposed TWE Project transmission
path would facilitate delivery of,
including type(s) of resources, general
location of generation and load or
markets, existing interconnection
requests, anticipated resource capacity
and capacity factor of resource,
estimated commercial operation date of
generation, and any other information
that would be useful in evaluating
submitted SOIs.
5. The amount of transmission
capacity and desired term of agreement
for long-term firm transmission service
and the interconnection or receipt
points on the proposed path.
6. A general description of financing
for generation.
7. A statement of financial stability.
Entities intending to submit a SOI
should request from Western a SOI
Evaluation Agreement. Entities must
then execute the SOI Evaluation
Agreement and pay a non-refundable
SOI Evaluation Cost in the sum of
$5,000. Western intends to use these
funds to defray its cost in evaluating the
SOIs and to continue its efforts in
considering its potential participation in
the TWE Project. By submitting an SOI
and associated Evaluation Cost,
submitters will be included for future
consideration for Western’s capacity in
the TWE Project should the project
proceed and Western participate in it.
Western will treat data submitted by
entities in this process, including
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
63827
financing arrangements with other
parties, in accordance with the Freedom
of Information Act (FOIA). Participants
may identify for confidential treatment
all or part of a submitted document
under the FOIA exemption for
‘‘Confidential Business Information’’
with appropriate markings. Such
markings will be considered in the
event a FOIA request for the information
is received.
Environmental Compliance
In compliance with the National
Environmental Policy Act of 1969
(NEPA) (42 U.S.C. 4321, et seq.), the
Council on Environmental Quality
Regulations for implementing NEPA (40
CFR Parts 1500–1508) and the DOE
NEPA Implementing Procedures and
Guidelines (10 CFR Part 1021), Western
has determined that this action is
categorically excluded from further
NEPA analysis. Future actions under
this authority will undergo appropriate
NEPA analysis.
Dated: October 7, 2010.
Timothy J. Meeks,
Administrator.
[FR Doc. 2010–26143 Filed 10–15–10; 8:45 am]
BILLING CODE 6450–01–P
ENVIRONMENTAL PROTECTION
AGENCY
[FRL–9214–5; Docket ID No. EPA–HQ–ORD–
2010–0744]
Integrated Risk Information System
(IRIS); Request for Chemical
Substance Nominations for 2011
Program
Environmental Protection
Agency (EPA).
ACTION: Request for chemical substance
nominations for the IRIS 2011 Program.
AGENCY:
EPA’s IRIS is a human health
assessment program that evaluates
quantitative and qualitative risk
information on effects that may result
from exposure to specific chemical
substances found in the environment.
EPA is soliciting public nominations for
chemical substances for its 2011 agenda.
EPA invites the public to submit
nominations for substances to be
considered for an assessment or
reassessment in its IRIS Program in
accordance with the instructions
provided at the end of this notice.
DATES: Nominations must be submitted
within 60 days of the publication of this
notice. The 60-day period begins
October 18, 2010, and ends December
17, 2010.
SUMMARY:
E:\FR\FM\18OCN1.SGM
18OCN1
63828
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
Nominations may be
submitted electronically via https://
www.regulations.gov, by e-mail, by mail,
by facsimile, or by hand delivery/
courier. Please follow the detailed
instructions provided in the
SUPPLEMENTARY INFORMATION section of
this notice.
FOR FURTHER INFORMATION CONTACT: For
information on the IRIS Program,
contact Abdel Kadry, PhD, Program
Director, National Center for
Environmental Assessment (mail code
8601PY), Office of Research and
Development, U.S. Environmental
Protection Agency, Washington, DC
20460; or send electronic mail inquiries
to: FRNquestions@epa.gov. For general
questions about access to IRIS or the
content of IRIS, please call the IRIS
ADDRESSES:
Hotline at (202) 566–1676 or send
electronic mail inquiries to
hotline.iris@epa.gov.
SUPPLEMENTARY INFORMATION:
I. Background
EPA’s IRIS is a human health
assessment program that evaluates
quantitative and qualitative risk
information on effects that may result
from exposure to specific chemical
substances found in the environment.
Through the IRIS Program, EPA
provides the highest quality sciencebased human health assessments to
support the Agency’s regulatory
activities. The IRIS database contains
information for more than 540 chemical
substances that can be used to support
the first two steps (hazard identification
and dose-response evaluation) of the
risk assessment process. When
supported by available data, IRIS
provides oral reference doses (RfDs) and
inhalation reference concentrations
(RfCs) for chronic noncancer health
effects, as well as assessments of
potential carcinogenic effects resulting
from chronic exposure. Combined with
specific exposure information,
government and private entities use IRIS
to help characterize public health risks
of chemical substances in site-specific
situations and thereby support risk
management decisions designed to
protect public health.
From FY2008 to the present, the
following IRIS assessments were
completed and posted on the IRIS
database:
acrylamide .......................................................................................................................................................................
bromobenzene ................................................................................................................................................................
carbon tetrachloride ........................................................................................................................................................
cerium oxide and cerium compounds ............................................................................................................................
chlordecone (kepone) .....................................................................................................................................................
chloroprene .....................................................................................................................................................................
decabromodiphenyl ether ...............................................................................................................................................
cis-1,2-dichloroethylene ..................................................................................................................................................
trans-1,2-dichloroethylene ..............................................................................................................................................
1,4-dioxane (oral) ............................................................................................................................................................
ethylene glycol monobutyl ether (EGBE) .......................................................................................................................
hexabromodiphenyl ether ...............................................................................................................................................
2-hexanone .....................................................................................................................................................................
hydrogen cyanide ...........................................................................................................................................................
nitrobenzene ...................................................................................................................................................................
pentabromodiphenyl ether ..............................................................................................................................................
pentachlorophenol ..........................................................................................................................................................
propionaldehyde .............................................................................................................................................................
tetrabromodiphenyl ether ................................................................................................................................................
1,1,2,2-tetrachloroethane ................................................................................................................................................
thallium ............................................................................................................................................................................
1,2,3-trichloropropane .....................................................................................................................................................
mstockstill on DSKH9S0YB1PROD with NOTICES
The assessments listed below are
currently on the IRIS agenda. The status
and planned milestone dates can be
found on the IRIS track system,
accessible on the IRIS Web site (https://
www.epa.gov/iris). All cancer and
noncancer health endpoints due to
chronic exposure are being assessed
unless otherwise noted. Not all of the
assessments on the IRIS agenda have
been started, but most are in the various
review steps of the IRIS process. The
remainder will start draft development
as resources become available.
acetaldehyde ...................................................................................................................................................................
acrylonitrile ......................................................................................................................................................................
alkylates ..........................................................................................................................................................................
ammonia .........................................................................................................................................................................
tert-amyl methyl ether (TAME) .......................................................................................................................................
antimony .........................................................................................................................................................................
arsenic, inorganic (cancer) .............................................................................................................................................
arsenic, inorganic (noncancer) .......................................................................................................................................
benzo(a)pyrene ...............................................................................................................................................................
beryllium (cancer) ...........................................................................................................................................................
biphenyl ...........................................................................................................................................................................
bisphenol A .....................................................................................................................................................................
n-butanol .........................................................................................................................................................................
tert-butanol ......................................................................................................................................................................
butyl benzyl phthalate .....................................................................................................................................................
cadmium .........................................................................................................................................................................
carbonyl sulfide ...............................................................................................................................................................
chloroethane ...................................................................................................................................................................
chloroform .......................................................................................................................................................................
chromium VI ....................................................................................................................................................................
cobalt ..............................................................................................................................................................................
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
79–06–1
108–86–1
56–23–5
1306–38–3
143–50–0
126–99–8
1163–19–5
156–59–2
156–60–5
123–91–1
111–76–2
68631–49–2
591–78–6
74–90–8
98–95–3
60348–60–9
87–86–5
123–38–6
5436–43–1
79–34–5
7440–28–0
96–18–4
E:\FR\FM\18OCN1.SGM
18OCN1
75–07–0
107–13–1
various
7664–41–7
994–05–8
7440–36–0
7440–38–2
7440–38–2
50–32–8
7440–41–7
92–52–4
80–05–7
71–36–3
75–65–0
85–68–7
7440–43–9
463–58–1
75–00–3
67–66–3
18540–29–9
7440–48–4
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
copper .............................................................................................................................................................................
di-n-butyl phthalate .........................................................................................................................................................
1,2-dichlorobenzene .......................................................................................................................................................
1,3-dichlorobenzene .......................................................................................................................................................
1,4-dichlorobenzene .......................................................................................................................................................
1,2-dichloroethane (ethylene dichloride) ........................................................................................................................
dichloromethane (methylene chloride) ...........................................................................................................................
diethyl phthalate ..............................................................................................................................................................
di(2-ethylhexyl)adipate ....................................................................................................................................................
di(2-ethylhexyl) phthalate ................................................................................................................................................
diisobutyl phthalate .........................................................................................................................................................
diisononyl phthalate ........................................................................................................................................................
diisopropyl ether (DIPE) .................................................................................................................................................
4,4’-dimethyl-3-oxahexane (TAEE) .................................................................................................................................
1,4-dioxane (inhalation) ..................................................................................................................................................
dipentyl phthalate ............................................................................................................................................................
ethanol ............................................................................................................................................................................
ethyl tertiary butyl ether (ETBE) .....................................................................................................................................
ethylbenzene ...................................................................................................................................................................
ethylene oxide (cancer) ..................................................................................................................................................
formaldehyde ..................................................................................................................................................................
hexabromocyclododecane (mixed stereoisomers) .........................................................................................................
hexachlorobutadiene .......................................................................................................................................................
hexachloroethane ...........................................................................................................................................................
hexahydro-1,3,5-trinitro-triazine (RDX) ...........................................................................................................................
isopropanol .....................................................................................................................................................................
Libby amphibole asbestos ..............................................................................................................................................
manganese .....................................................................................................................................................................
methanol .........................................................................................................................................................................
methyl tert-butyl ether (MTBE) .......................................................................................................................................
mirex ...............................................................................................................................................................................
naphthalene ....................................................................................................................................................................
nickel (soluble salts) .......................................................................................................................................................
halogenated platinum salts and platinum compounds ...................................................................................................
polychlorinated biphenyls (PCBs) (noncancer) ..............................................................................................................
polycyclic aromatic hydrocarbon (PAH) mixtures ...........................................................................................................
refractory ceramic fibers .................................................................................................................................................
styrene ............................................................................................................................................................................
2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds .........................................................................................
tetrachloroethylene (perchloroethylene) .........................................................................................................................
tetrahydrofuran ................................................................................................................................................................
trichloroacetic acid ..........................................................................................................................................................
trichloroethylene ..............................................................................................................................................................
1,2,4-trimethylbenzene ...................................................................................................................................................
1,3,5-trimethylbenzene ...................................................................................................................................................
tungsten and related compounds ...................................................................................................................................
urea .................................................................................................................................................................................
uranium (natural) ............................................................................................................................................................
vanadium pentoxide ........................................................................................................................................................
vinyl acetate ....................................................................................................................................................................
The alkylates, listed above, are a
distillation fraction of petroleum and
are present in gasoline. Common
alkylates found in gasoline for which
IRIS assessments have not been recently
completed include n-heptane,
methylcyclohexane, 2-methylbutane, 2methylpentane, 3-methylpentane, noctane, 2,3,3-trimethylpentane, 2,3,4trimethylpentane, and 2,2,5trimethylhexane. EPA will evaluate the
feasibility of conducting an assessment
of alkylates, the approach to be taken in
the assessment, and the identities of the
compounds that will be assessed.
The following phthalates have been
added to the IRIS agenda: Diisobutyl
phthalate, diisononyl phthalate, and
dipentyl phthalate. These additions to
the IRIS agenda are in response to
recommendations made by the National
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
Academy of Sciences in the report,
‘‘Phthalates and Cumulative Risk
Assessment—The Tasks Ahead’’ (NAS,
2008).
Perfluorooctanoic acid—ammonium
salt (PFOA) and perfluorooctane
sulfonate—potassium salt (PFOS) have
been withdrawn from the IRIS agenda.
In December 2009, EPA published the
‘‘Long-Chain Perfluorinated Chemicals
(PFCs) Action Plan Summary’’ (https://
www.epa.gov/opptintr/
existingchemicals/pubs/actionplans/
pfcs.html), part of EPA Administrator
Lisa Jackson’s comprehensive approach
to enhance the Agency’s current
chemicals management program under
the Toxic Substances Control Act. PFOA
and PFOS are included in the Agency’s
action plan for this class of chemicals.
The listing of asbestos in the IRIS
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
63829
7440–50–8
84–74–2
95–50–1
541–73–1
106–46–7
107–06–2
75–09–2
84–66–2
103–23–1
117–81–7
84–69–5
58033–90–2
108–20–3
919–94–8
123–91–1
131–18–0
64–17–5
637–92–3
100–41–4
75–21–8
50–00–0
3194–55–6, 25637–99–5
87–68–3
67–72–1
121–82–4
67–63–0
1332–21–4
7439–9
l67–56–1
1634–04–4
2385–85–5
91–20–3
various
various
various
various
not applicable
100–42–5
1746–01–6, various
127–18–4
109–99–9
76–03–9
79–01–6
95–63–6
108–67–8
7440–33–7, various
57–13–6
7440–61–1
1314–62–1
108–05–4
agenda has been revised to specify
Libby amphibole asbestos. EPA is
focusing on the Libby amphibole in
order to respond to needs of the Agency
and the Libby community. The
assessment for weathered toxaphene has
been withdrawn because of lack of data
to support an IRIS assessment.
Today’s notice invites voluntary
public nominations for chemical
substances not already listed in this
notice. Today’s notice also invites
comments on assessments on the
current IRIS agenda. To nominate a
substance, please complete the form
below and submit it to EPA by one of
the methods detailed below. A fill-andprint version of this form can be found
on the IRIS Web site, https://www.epa.
gov/iris, under IRIS Agenda.
Nominations and comments are most
E:\FR\FM\18OCN1.SGM
18OCN1
63830
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
useful if they identify the nominator
(including full name, title, affiliation,
mailing address, e-mail address, and
telephone number) and provide
information on the criteria EPA uses to
evaluate the priority of the chemicals:
Identification of nominator:
Nominator’s name:
Title:
Affiliation:
Telephone No.:
Address:
e-mail address:
Chemical Substance Name:
Common Synonym(s), if any:
CAS No.:
Information for Prioritizing
Nominations
mstockstill on DSKH9S0YB1PROD with NOTICES
1. What is the potential public health
impact for this chemical?
2. Is this assessment needed to fulfill
a chemical-specific EPA mandate or
program need (e.g., statutory, regulatory,
or court-ordered deadline)? Please
describe the mandate or program need.
When is the assessment needed?
3. Is this assessment a priority for
stakeholders outside of EPA (e.g., states,
tribes, local governments,
environmental organizations, industries,
or other IRIS users)? Why is it a
priority?
4. Are you aware of other assessments
of this substance that may be available
to EPA (e.g., an EPA program has
assessed this substance, but it has not
received Agency-wide IRIS review, a
state or other federal agency has an
assessment, or another government or
private organization has assessed this
substance)? If possible, please provide
specific information to allow EPA to
locate and obtain the assessment.
5. For substances being nominated for
IRIS reassessment, what, if any,
significant new scientific data or risk
assessment methodology is available
that you believe would be likely to
appreciably change the existing IRIS
assessment? Please provide specific
citations and other information that
would allow EPA to locate and obtain
the papers or data.
6. Are you aware of other factors that
would make this substance a priority for
IRIS assessment (e.g., widespread
exposure, expected toxicity, or
potentially susceptible populations)?
II. How To Submit Nominations and
Comments to the Docket at https://www.
regulations.gov
—https://www.regulations.gov: Follow
the on-line instructions for submitting
comments.
—E-Mail: ORD.Docket@epa.gov.
—Hand Delivery: The OEI Docket is
located in the EPA Headquarters
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
Docket Center, EPA West Building,
Room 3334, 1301 Constitution Ave.,
NW., Washington, DC. The EPA
Docket Center Public Reading Room is
open from 8:30 a.m. to 4:30 p.m.,
Eastern Standard Time, Monday
through Friday, excluding federal
holidays. The telephone number for
the Public Reading Room is (202)
566–1744. Deliveries are only
accepted during the docket’s normal
hours of operation, and special
arrangements should be made for
deliveries of boxed information.
Consult EPA’s Web site at https://www.
epa.gov/epahome/dockets.htm for
current information on docket
operations, locations and telephone
numbers.
Instructions: Direct your nominations
to Docket ID No. EPA–HQ–ORD–2010–
0744. Please ensure that your comments
are submitted within the specified
nomination period. Nominations
received after the closing date will be
marked ‘‘late,’’ and may be considered
only if time permits. It is EPA’s policy
to include all comments it receives in
the public docket without change and to
make the comments available online at
https://www.regulations.gov, including
any personal information provided,
unless comments include information
claimed to be Confidential Business
Information (CBI) or other information
whose disclosure is restricted by statute.
Do not submit information that you
consider to be CBI or otherwise
protected through https://www.
regulations.gov or e-mail. The https://
www.regulations.gov Web site is an
‘‘anonymous access’’ system, which
means EPA will not know your identity
or contact information unless you
provide it in the body of your
comments. If you send e-mail comments
directly to EPA without going through
https://www.regulations.gov, your e-mail
address will be automatically captured
and included as part of the comments
that are placed in the public docket and
made available on the Internet. If you
submit electronic comments, EPA
recommends that you include your
name and other contact information in
the body of your comments and with
any disk or CD–ROM you submit. If EPA
cannot read your comments due to
technical difficulties and cannot contact
you for clarification, EPA may not be
able to consider your comments.
Electronic files should avoid the use of
special characters, any form of
encryption, and be free of any defects or
viruses. For additional information
about EPA’s public docket, visit the EPA
Docket Center homepage at https://www.
epa.gov/epahome/dockets.htm.
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Docket: Documents in the docket are
listed in the https://www.regulations.gov
index. Although listed in the index,
some information is not publicly
available, e.g., CBI or other information
whose disclosure is restricted by statute.
Certain other materials, such as
copyrighted material, are publicly
available only in hard copy. Publicly
available docket materials are available
either electronically in https://www.
regulations.gov or in hard copy at the
OEI Docket in the EPA Headquarters
Docket Center.
Dated: October 12, 2010.
Darrell Winner,
Acting Director, National Center for
Environmental Assessment.
[FR Doc. 2010–26159 Filed 10–15–10; 8:45 am]
BILLING CODE 6560–50–P
FEDERAL COMMUNICATIONS
COMMISSION
[DA 10–1937]
Consumer Advisory Committee
Federal Communications
Commission.
ACTION: Notice.
AGENCY:
The Commission announces
the next meeting date and agenda of its
Consumer Advisory Committee
(‘‘Committee’’). The purpose of the
Committee is to make recommendations
to the Commission regarding consumer
issues within the jurisdiction of the
Commission and to facilitate the
participation of all consumers in
proceedings before the Commission.
DATES: The meeting of the Committee
will take place on Wednesday,
November 10, 2010, 9 a.m. to 4 p.m., at
the Commission’s Headquarters
Building, Room TW–C305.
ADDRESSES: Federal Communications
Commission, 445 12th Street, SW.,
Washington, DC 20554.
FOR FURTHER INFORMATION CONTACT:
Scott Marshall, Consumer and
Governmental Affairs Bureau, (202)
418–2809 (voice), (202) 418–0179
(TTY), or e-mail Scott.Marshall@fcc.gov.
SUPPLEMENTARY INFORMATION: This is a
summary of the Commission’s
document DA 10–1937 released October
7, 2010, announcing the agenda, date
and time of the Committee’s next
meeting. At its November 10, 2010
meeting, the Committee is expected to
consider a recommendation regarding a
pilot project aimed at identifying
methods and strategies to improve
federal/state collaboration on consumer
complaint processing. A 2nd
SUMMARY:
E:\FR\FM\18OCN1.SGM
18OCN1
]]>Agencies
[Federal Register Volume 75, Number 200 (Monday, October 18, 2010)]
[Notices]
[Pages 63827-63830]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26159]
=======================================================================
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
[FRL-9214-5; Docket ID No. EPA-HQ-ORD-2010-0744]
Integrated Risk Information System (IRIS); Request for Chemical
Substance Nominations for 2011 Program
AGENCY: Environmental Protection Agency (EPA).
ACTION: Request for chemical substance nominations for the IRIS 2011
Program.
-----------------------------------------------------------------------
SUMMARY: EPA's IRIS is a human health assessment program that evaluates
quantitative and qualitative risk information on effects that may
result from exposure to specific chemical substances found in the
environment. EPA is soliciting public nominations for chemical
substances for its 2011 agenda. EPA invites the public to submit
nominations for substances to be considered for an assessment or
reassessment in its IRIS Program in accordance with the instructions
provided at the end of this notice.
DATES: Nominations must be submitted within 60 days of the publication
of this notice. The 60-day period begins October 18, 2010, and ends
December 17, 2010.
[[Page 63828]]
ADDRESSES: Nominations may be submitted electronically via https://www.regulations.gov, by e-mail, by mail, by facsimile, or by hand
delivery/courier. Please follow the detailed instructions provided in
the SUPPLEMENTARY INFORMATION section of this notice.
FOR FURTHER INFORMATION CONTACT: For information on the IRIS Program,
contact Abdel Kadry, PhD, Program Director, National Center for
Environmental Assessment (mail code 8601PY), Office of Research and
Development, U.S. Environmental Protection Agency, Washington, DC
20460; or send electronic mail inquiries to: FRNquestions@epa.gov. For
general questions about access to IRIS or the content of IRIS, please
call the IRIS Hotline at (202) 566-1676 or send electronic mail
inquiries to hotline.iris@epa.gov.
SUPPLEMENTARY INFORMATION:
I. Background
EPA's IRIS is a human health assessment program that evaluates
quantitative and qualitative risk information on effects that may
result from exposure to specific chemical substances found in the
environment. Through the IRIS Program, EPA provides the highest quality
science-based human health assessments to support the Agency's
regulatory activities. The IRIS database contains information for more
than 540 chemical substances that can be used to support the first two
steps (hazard identification and dose-response evaluation) of the risk
assessment process. When supported by available data, IRIS provides
oral reference doses (RfDs) and inhalation reference concentrations
(RfCs) for chronic noncancer health effects, as well as assessments of
potential carcinogenic effects resulting from chronic exposure.
Combined with specific exposure information, government and private
entities use IRIS to help characterize public health risks of chemical
substances in site-specific situations and thereby support risk
management decisions designed to protect public health.
From FY2008 to the present, the following IRIS assessments were
completed and posted on the IRIS database:
------------------------------------------------------------------------
------------------------------------------------------------------------
acrylamide........................ 79-06-1
bromobenzene...................... 108-86-1
carbon tetrachloride.............. 56-23-5
cerium oxide and cerium compounds. 1306-38-3
chlordecone (kepone).............. 143-50-0
chloroprene....................... 126-99-8
decabromodiphenyl ether........... 1163-19-5
cis-1,2-dichloroethylene.......... 156-59-2
trans-1,2-dichloroethylene........ 156-60-5
1,4-dioxane (oral)................ 123-91-1
ethylene glycol monobutyl ether 111-76-2
(EGBE).
hexabromodiphenyl ether........... 68631-49-2
2-hexanone........................ 591-78-6
hydrogen cyanide.................. 74-90-8
nitrobenzene...................... 98-95-3
pentabromodiphenyl ether.......... 60348-60-9
pentachlorophenol................. 87-86-5
propionaldehyde................... 123-38-6
tetrabromodiphenyl ether.......... 5436-43-1
1,1,2,2-tetrachloroethane......... 79-34-5
thallium.......................... 7440-28-0
1,2,3-trichloropropane............ 96-18-4
------------------------------------------------------------------------
The assessments listed below are currently on the IRIS agenda. The
status and planned milestone dates can be found on the IRIS track
system, accessible on the IRIS Web site (https://www.epa.gov/iris). All
cancer and noncancer health endpoints due to chronic exposure are being
assessed unless otherwise noted. Not all of the assessments on the IRIS
agenda have been started, but most are in the various review steps of
the IRIS process. The remainder will start draft development as
resources become available.
------------------------------------------------------------------------
------------------------------------------------------------------------
acetaldehyde...................... 75-07-0
acrylonitrile..................... 107-13-1
alkylates......................... various
ammonia........................... 7664-41-7
tert-amyl methyl ether (TAME)..... 994-05-8
antimony.......................... 7440-36-0
arsenic, inorganic (cancer)....... 7440-38-2
arsenic, inorganic (noncancer).... 7440-38-2
benzo(a)pyrene.................... 50-32-8
beryllium (cancer)................ 7440-41-7
biphenyl.......................... 92-52-4
bisphenol A....................... 80-05-7
n-butanol......................... 71-36-3
tert-butanol...................... 75-65-0
butyl benzyl phthalate............ 85-68-7
cadmium........................... 7440-43-9
carbonyl sulfide.................. 463-58-1
chloroethane...................... 75-00-3
chloroform........................ 67-66-3
chromium VI....................... 18540-29-9
cobalt............................ 7440-48-4
[[Page 63829]]
copper............................ 7440-50-8
di-n-butyl phthalate.............. 84-74-2
1,2-dichlorobenzene............... 95-50-1
1,3-dichlorobenzene............... 541-73-1
1,4-dichlorobenzene............... 106-46-7
1,2-dichloroethane (ethylene 107-06-2
dichloride).
dichloromethane (methylene 75-09-2
chloride).
diethyl phthalate................. 84-66-2
di(2-ethylhexyl)adipate........... 103-23-1
di(2-ethylhexyl) phthalate........ 117-81-7
diisobutyl phthalate.............. 84-69-5
diisononyl phthalate.............. 58033-90-2
diisopropyl ether (DIPE).......... 108-20-3
4,4'-dimethyl-3-oxahexane (TAEE).. 919-94-8
1,4-dioxane (inhalation).......... 123-91-1
dipentyl phthalate................ 131-18-0
ethanol........................... 64-17-5
ethyl tertiary butyl ether (ETBE). 637-92-3
ethylbenzene...................... 100-41-4
ethylene oxide (cancer)........... 75-21-8
formaldehyde...................... 50-00-0
hexabromocyclododecane (mixed 3194-55-6, 25637-99-5
stereoisomers).
hexachlorobutadiene............... 87-68-3
hexachloroethane.................. 67-72-1
hexahydro-1,3,5-trinitro-triazine 121-82-4
(RDX).
isopropanol....................... 67-63-0
Libby amphibole asbestos.......... 1332-21-4
manganese......................... 7439-9
methanol.......................... l67-56-1
methyl tert-butyl ether (MTBE).... 1634-04-4
mirex............................. 2385-85-5
naphthalene....................... 91-20-3
nickel (soluble salts)............ various
halogenated platinum salts and various
platinum compounds.
polychlorinated biphenyls (PCBs) various
(noncancer).
polycyclic aromatic hydrocarbon various
(PAH) mixtures.
refractory ceramic fibers......... not applicable
styrene........................... 100-42-5
2,3,7,8-tetrachlorodibenzo-p- 1746-01-6, various
dioxin and related compounds.
tetrachloroethylene 127-18-4
(perchloroethylene).
tetrahydrofuran................... 109-99-9
trichloroacetic acid.............. 76-03-9
trichloroethylene................. 79-01-6
1,2,4-trimethylbenzene............ 95-63-6
1,3,5-trimethylbenzene............ 108-67-8
tungsten and related compounds.... 7440-33-7, various
urea.............................. 57-13-6
uranium (natural)................. 7440-61-1
vanadium pentoxide................ 1314-62-1
vinyl acetate..................... 108-05-4
------------------------------------------------------------------------
The alkylates, listed above, are a distillation fraction of
petroleum and are present in gasoline. Common alkylates found in
gasoline for which IRIS assessments have not been recently completed
include n-heptane, methylcyclohexane, 2-methylbutane, 2-methylpentane,
3-methylpentane, n-octane, 2,3,3-trimethylpentane, 2,3,4-
trimethylpentane, and 2,2,5-trimethylhexane. EPA will evaluate the
feasibility of conducting an assessment of alkylates, the approach to
be taken in the assessment, and the identities of the compounds that
will be assessed.
The following phthalates have been added to the IRIS agenda:
Diisobutyl phthalate, diisononyl phthalate, and dipentyl phthalate.
These additions to the IRIS agenda are in response to recommendations
made by the National Academy of Sciences in the report, ``Phthalates
and Cumulative Risk Assessment--The Tasks Ahead'' (NAS, 2008).
Perfluorooctanoic acid--ammonium salt (PFOA) and perfluorooctane
sulfonate--potassium salt (PFOS) have been withdrawn from the IRIS
agenda. In December 2009, EPA published the ``Long-Chain Perfluorinated
Chemicals (PFCs) Action Plan Summary'' (https://www.epa.gov/opptintr/existingchemicals/pubs/actionplans/pfcs.html), part of EPA
Administrator Lisa Jackson's comprehensive approach to enhance the
Agency's current chemicals management program under the Toxic
Substances Control Act. PFOA and PFOS are included in the Agency's
action plan for this class of chemicals. The listing of asbestos in the
IRIS agenda has been revised to specify Libby amphibole asbestos. EPA
is focusing on the Libby amphibole in order to respond to needs of the
Agency and the Libby community. The assessment for weathered toxaphene
has been withdrawn because of lack of data to support an IRIS
assessment.
Today's notice invites voluntary public nominations for chemical
substances not already listed in this notice. Today's notice also
invites comments on assessments on the current IRIS agenda. To nominate
a substance, please complete the form below and submit it to EPA by one
of the methods detailed below. A fill-and-print version of this form
can be found on the IRIS Web site, https://www.epa.gov/iris, under IRIS
Agenda. Nominations and comments are most
[[Page 63830]]
useful if they identify the nominator (including full name, title,
affiliation, mailing address, e-mail address, and telephone number) and
provide information on the criteria EPA uses to evaluate the priority
of the chemicals:
Identification of nominator:
Nominator's name:
Title:
Affiliation:
Telephone No.:
Address:
e-mail address:
Chemical Substance Name:
Common Synonym(s), if any:
CAS No.:
Information for Prioritizing Nominations
1. What is the potential public health impact for this chemical?
2. Is this assessment needed to fulfill a chemical-specific EPA
mandate or program need (e.g., statutory, regulatory, or court-ordered
deadline)? Please describe the mandate or program need. When is the
assessment needed?
3. Is this assessment a priority for stakeholders outside of EPA
(e.g., states, tribes, local governments, environmental organizations,
industries, or other IRIS users)? Why is it a priority?
4. Are you aware of other assessments of this substance that may be
available to EPA (e.g., an EPA program has assessed this substance, but
it has not received Agency-wide IRIS review, a state or other federal
agency has an assessment, or another government or private organization
has assessed this substance)? If possible, please provide specific
information to allow EPA to locate and obtain the assessment.
5. For substances being nominated for IRIS reassessment, what, if
any, significant new scientific data or risk assessment methodology is
available that you believe would be likely to appreciably change the
existing IRIS assessment? Please provide specific citations and other
information that would allow EPA to locate and obtain the papers or
data.
6. Are you aware of other factors that would make this substance a
priority for IRIS assessment (e.g., widespread exposure, expected
toxicity, or potentially susceptible populations)?
II. How To Submit Nominations and Comments to the Docket at https://www.regulations.gov
--https://www.regulations.gov: Follow the on-line instructions for
submitting comments.
--E-Mail: ORD.Docket@epa.gov.
--Hand Delivery: The OEI Docket is located in the EPA Headquarters
Docket Center, EPA West Building, Room 3334, 1301 Constitution Ave.,
NW., Washington, DC. The EPA Docket Center Public Reading Room is open
from 8:30 a.m. to 4:30 p.m., Eastern Standard Time, Monday through
Friday, excluding federal holidays. The telephone number for the Public
Reading Room is (202) 566-1744. Deliveries are only accepted during the
docket's normal hours of operation, and special arrangements should be
made for deliveries of boxed information. Consult EPA's Web site at
https://www.epa.gov/epahome/dockets.htm for current information on
docket operations, locations and telephone numbers.
Instructions: Direct your nominations to Docket ID No. EPA-HQ-ORD-
2010-0744. Please ensure that your comments are submitted within the
specified nomination period. Nominations received after the closing
date will be marked ``late,'' and may be considered only if time
permits. It is EPA's policy to include all comments it receives in the
public docket without change and to make the comments available online
at https://www.regulations.gov, including any personal information
provided, unless comments include information claimed to be
Confidential Business Information (CBI) or other information whose
disclosure is restricted by statute. Do not submit information that you
consider to be CBI or otherwise protected through https://www.regulations.gov or e-mail. The https://www.regulations.gov Web site
is an ``anonymous access'' system, which means EPA will not know your
identity or contact information unless you provide it in the body of
your comments. If you send e-mail comments directly to EPA without
going through https://www.regulations.gov, your e-mail address will be
automatically captured and included as part of the comments that are
placed in the public docket and made available on the Internet. If you
submit electronic comments, EPA recommends that you include your name
and other contact information in the body of your comments and with any
disk or CD-ROM you submit. If EPA cannot read your comments due to
technical difficulties and cannot contact you for clarification, EPA
may not be able to consider your comments. Electronic files should
avoid the use of special characters, any form of encryption, and be
free of any defects or viruses. For additional information about EPA's
public docket, visit the EPA Docket Center homepage at https://www.epa.gov/epahome/dockets.htm.
Docket: Documents in the docket are listed in the https://www.regulations.gov index. Although listed in the index, some
information is not publicly available, e.g., CBI or other information
whose disclosure is restricted by statute. Certain other materials,
such as copyrighted material, are publicly available only in hard copy.
Publicly available docket materials are available either electronically
in https://www.regulations.gov or in hard copy at the OEI Docket in the
EPA Headquarters Docket Center.
Dated: October 12, 2010.
Darrell Winner,
Acting Director, National Center for Environmental Assessment.
[FR Doc. 2010-26159 Filed 10-15-10; 8:45 am]
BILLING CODE 6560-50-P
